Breaking News Instant updates and real-time market news.

BY

Byline Bancorp

$15.79 /

-0.045 (-0.28%)

08:05
12/11/20
12/11
08:05
12/11/20
08:05

Byline Bancorp announces up to 1.25M share stock repurchase program

Byline Bancorp announced that its board has approved a new stock repurchase program that authorizes the company to repurchase up to 1.25M shares of the company's outstanding common stock. The shares authorized to be repurchased represent approximately 3.2% of the company's currently outstanding common stock. The new program will be effective January 1, 2021 and be in effect until December 31, 2022. Under its existing stock repurchase program expiring on December 31, Byline has purchased 118,486 shares of the 1.25M total shares authorized for repurchase.

BY Byline Bancorp
$15.79 /

-0.045 (-0.28%)

12/19/19 Stephens
Byline Bancorp upgraded to Overweight from Equal Weight at Stephens

TODAY'S FREE FLY STORIES

General news
Asian Market Update: » 01:45
01/22/21
01/22
01:45
01/22/21
01:45

Asian Market Update: The…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
U.S. Markit PMI preview » 01:45
01/22/21
01/22
01:45
01/22/21
01:45

U.S. Markit PMI preview:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

General news
U.S. existing home sales preview » 01:45
01/22/21
01/22
01:45
01/22/21
01:45

U.S. existing home sales…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Syndicate
Azek 20M share Secondary priced at $40.00 » 23:07
01/21/21
01/21
23:07
01/21/21
23:07
AZEK

Azek

$41.20 /

-0.525 (-1.26%)

The deal size was…

The deal size was increased to 20M shares from 17.5M and priced below the last closing price of $41.13. Barclays, BofA, Goldman Sachs and Jefferies are acting as joint book running managers for the offering.

ShowHide Related Items >><<
AZEK Azek
$41.20 /

-0.525 (-1.26%)

AZEK Azek
$41.20 /

-0.525 (-1.26%)

01/13/21 BMO Capital
Azek initiated with an Outperform at BMO Capital
12/31/20 William Blair
Azek, Trex among Blair's top Specialty Distribution ideas for 2021
12/04/20 DA Davidson
Azek price target raised to $39 from $33 at DA Davidson
12/04/20 B. Riley Securities
Azek price target raised to $46 from $43 at B. Riley Securities
AZEK Azek
$41.20 /

-0.525 (-1.26%)

  • 22
    Jan
  • 11
    Sep
  • 12
    Jun
AZEK Azek
$41.20 /

-0.525 (-1.26%)

AZEK Azek
$41.20 /

-0.525 (-1.26%)

AZEK Azek
$41.20 /

-0.525 (-1.26%)

Upgrade
Land Securities upgraded to Buy from Hold at Deutsche Bank » 21:24
01/21/21
01/21
21:24
01/21/21
21:24
LDSCY

Land Securities

$0.00 /

+ (+0.00%)

Deutsche Bank analyst…

Deutsche Bank analyst Nithin Devaraj upgraded Land Securities to Buy from Hold with an unchanged price target of 730 GBp. The market is assigning too high a discount to its non-office exposure, Devaraj tells investors in a research note.

ShowHide Related Items >><<
LDSCY Land Securities
$0.00 /

+ (+0.00%)

01/15/21 JPMorgan
Land Securities price target raised to 800 GBp from 650 GBp at JPMorgan
01/05/21 Morgan Stanley
Land Securities downgraded to Underweight from Equal Weight at Morgan Stanley
12/09/20 Jefferies
Land Securities price target raised to 785 GBp from 710 GBp at Jefferies
09/03/20 Morgan Stanley
Land Securities downgraded to Equal Weight from Overweight at Morgan Stanley
Upgrade
British Land upgraded to Buy from Hold at Deutsche Bank » 21:23
01/21/21
01/21
21:23
01/21/21
21:23
BTLCY

British Land

$0.00 /

+ (+0.00%)

Deutsche Bank analyst…

Deutsche Bank analyst Markus Scheufler upgraded British Land to Buy from Hold with an unchanged price target of 490 GBp. The stock is already trading at 35% discount to net asset value, so the market is already pricing in too much asset value downside, says the analyst.

ShowHide Related Items >><<
BTLCY British Land
$0.00 /

+ (+0.00%)

01/15/21 JPMorgan
British Land price target raised to 500 GBp from 430 GBp at JPMorgan
01/14/21 RBC Capital
British Land downgraded to Underperform from Sector Perform at RBC Capital
01/05/21 Morgan Stanley
British Land downgraded to Underweight from Equal Weight at Morgan Stanley
12/14/20 Peel Hunt
British Land downgraded to Hold from Add at Peel Hunt
Upgrade
Alstria Office upgraded to Buy from Hold at Deutsche Bank » 21:21
01/21/21
01/21
21:21
01/21/21
21:21
ALSRF

Alstria Office

$0.00 /

+ (+0.00%)

Deutsche Bank analyst…

Deutsche Bank analyst Markus Scheufler upgraded Alstria Office to Buy from Hold with a price target of EUR 19, up from EUR 18.50. The combination of management selling at a premium to book value in non-core locations, and a "stable to further improving outlook" for the German office market make for an attractive investment case, Scheufler tells investors in a research note.

ShowHide Related Items >><<
ALSRF Alstria Office
$0.00 /

+ (+0.00%)

01/05/21 Morgan Stanley
Alstria Office price target raised to EUR 15.50 from EUR 14.50 at Morgan Stanley
12/10/20 Goldman Sachs
Alstria Office upgraded to Buy from Neutral at Goldman Sachs
08/12/20 Deutsche Bank
alstria office price target lowered to EUR 18.50 from EUR 19.30 at Deutsche Bank
06/30/20 UBS
alstria office price target lowered to EUR 16.50 from EUR 19 at UBS
Syndicate
Aurora Cannabis 12M share Spot Secondary priced at $10.45 » 21:15
01/21/21
01/21
21:15
01/21/21
21:15
ACB

Aurora Cannabis

$11.17 /

-0.39 (-3.37%)

BMO Capital and ATB…

BMO Capital and ATB Capital Markets acted as joint book running managers for the offering.

ShowHide Related Items >><<
ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

01/06/21 BMO Capital
Federal cannabis reform in U.S. likely to take time, says BMO Capital
12/17/20 BMO Capital
Aurora Cannabis downgraded to Underperform from Market Perform at BMO Capital
12/04/20 Alliance Global Partners
Alliance Global sees low odds of MORE Act passing this congressional session
12/02/20 Alliance Global Partners
Alliance Global Partners sees UN cannabis reclassification helping legalization
ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

  • 22
    Jan
  • 11
    Nov
ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

Syndicate
Silvergate Capital 3.968M share Secondary priced at $63.00 » 21:13
01/21/21
01/21
21:13
01/21/21
21:13
SI

Silvergate Capital

$67.75 /

+1.25 (+1.88%)

The deal size was…

The deal size was increased to $250M in common stock from $200M in common stock. Goldman Sachs, Keefe Bruyette and Canaccord acted as joint book running managers for the offering.

ShowHide Related Items >><<
SI Silvergate Capital
$67.75 /

+1.25 (+1.88%)

SI Silvergate Capital
$67.75 /

+1.25 (+1.88%)

01/14/21 Barclays
Silvergate Capital downgraded to Equal Weight on valuation at Barclays
01/14/21 Barclays
Silvergate Capital downgraded to Equal Weight from Overweight at Barclays
01/07/21 Craig-Hallum
Silvergate Capital price target raised to $80 from $50 at Craig-Hallum
12/22/20
Fly Intel: Top five analyst initiations
SI Silvergate Capital
$67.75 /

+1.25 (+1.88%)

  • 22
    Jan
SI Silvergate Capital
$67.75 /

+1.25 (+1.88%)

SI Silvergate Capital
$67.75 /

+1.25 (+1.88%)

Syndicate
Corsair Gaming 7.5M share Secondary priced at $35.00 » 21:11
01/21/21
01/21
21:11
01/21/21
21:11
CRSR

Corsair Gaming

$36.88 /

+0.93 (+2.59%)

Goldman Sachs, Barclays,…

Goldman Sachs, Barclays, Credit Suisse, Macquarie, Baird, Cowen and Stifel acted as joint book running managers for the offering.

ShowHide Related Items >><<
CRSR Corsair Gaming
$36.88 /

+0.93 (+2.59%)

CRSR Corsair Gaming
$36.88 /

+0.93 (+2.59%)

12/15/20 Macquarie
Corsair Gaming price target raised to $42 from $30 at Macquarie
12/02/20 Cowen
Corsair Gaming downgraded to Market Perform at Cowen on valuation
12/02/20 Cowen
Corsair Gaming downgraded to Market Perform from Outperform at Cowen
12/01/20 Baird
Corsair Gaming price target raised to $41 from $30 at Baird
CRSR Corsair Gaming
$36.88 /

+0.93 (+2.59%)

  • 22
    Jan
  • 23
    Sep
CRSR Corsair Gaming
$36.88 /

+0.93 (+2.59%)

CRSR Corsair Gaming
$36.88 /

+0.93 (+2.59%)

Syndicate
RLX Technology 116.5M share IPO priced at $12.00 » 21:10
01/21/21
01/21
21:10
01/21/21
21:10
RLX

RLX Technology

$0.00 /

+ (+0.00%)

The priced above the…

The priced above the $8.00-$10.00 range. Citi acted as lead book running manager for the offering.

ShowHide Related Items >><<
  • 22
    Jan
Upgrade
Targa Resources upgraded to Buy from Hold at Stifel » 20:55
01/21/21
01/21
20:55
01/21/21
20:55
TRGP

Targa Resources

$28.75 /

-1.02 (-3.43%)

Stifel analyst Selman…

Stifel analyst Selman Akyol upgraded Targa Resources to Buy from Hold with a $34 price target.

ShowHide Related Items >><<
TRGP Targa Resources
$28.75 /

-1.02 (-3.43%)

TRGP Targa Resources
$28.75 /

-1.02 (-3.43%)

01/20/21 Mizuho
Targa Resources price target raised to $33 from $24 at Mizuho
01/13/21 JPMorgan
JPMorgan announces top 10 energy picks for 2021
01/13/21 Citi
Targa Resources price target raised to $36 from $22 at Citi
12/21/20 JPMorgan
Targa Resources price target raised to $37 from $33 at JPMorgan
TRGP Targa Resources
$28.75 /

-1.02 (-3.43%)

TRGP Targa Resources
$28.75 /

-1.02 (-3.43%)

Syndicate
Invitae 7.77M share Secondary priced at $51.50 » 20:42
01/21/21
01/21
20:42
01/21/21
20:42
NVTA

Invitae

$53.13 /

-3.75 (-6.59%)

The deal priced below the…

The deal priced below the last closing price of $53.13. JPMorgan, Morgan Stanley, Cowen and SVB Leerink are acting as joint book running managers for the offering.

ShowHide Related Items >><<
NVTA Invitae
$53.13 /

-3.75 (-6.59%)

NVTA Invitae
$53.13 /

-3.75 (-6.59%)

11/06/20 Ladenburg
Invitae downgraded to Neutral on valuation at Ladenburg
11/06/20 Ladenburg
Invitae downgraded to Neutral from Buy at Ladenburg
11/03/20 SVB Leerink
Invitae price target raised to $44 from $34 at SVB Leerink
10/14/20
Fly Intel: Top five analyst downgrades
NVTA Invitae
$53.13 /

-3.75 (-6.59%)

  • 22
    Jan
  • 02
    Apr
NVTA Invitae
$53.13 /

-3.75 (-6.59%)

NVTA Invitae
$53.13 /

-3.75 (-6.59%)

Earnings
Notable companies reporting before tomorrow's open » 20:25
01/21/21
01/21
20:25
01/21/21
20:25
SLB

Schlumberger

$24.18 /

-1.16 (-4.58%)

, KSU

Kansas City Southern

$212.74 /

-2.92 (-1.35%)

, RF

Regions Financial

$17.81 /

-0.33 (-1.82%)

, ALLY

Ally Financial

$39.93 /

-1.43 (-3.46%)

, HBAN

Huntington Bancshares

$14.51 /

-0.18 (-1.23%)

, FHN

First Horizon

$14.34 /

-0.36 (-2.45%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include Schlumberger (SLB), consensus 17c... Kansas City Southern (KSU), consensus $1.92... Regions Financial (RF), consensus 42c... Ally Financial (ALLY), consensus $1.05... Huntington Bancshares (HBAN), consensus 29c... First Horizon (FHN), consensus 33c.

ShowHide Related Items >><<
SLB Schlumberger
$24.18 /

-1.16 (-4.58%)

RF Regions Financial
$17.81 /

-0.33 (-1.82%)

KSU Kansas City Southern
$212.74 /

-2.92 (-1.35%)

HBAN Huntington Bancshares
$14.51 /

-0.18 (-1.23%)

FHN First Horizon
$14.34 /

-0.36 (-2.45%)

ALLY Ally Financial
$39.93 /

-1.43 (-3.46%)

SLB Schlumberger
$24.18 /

-1.16 (-4.58%)

12/18/20 JPMorgan
Schlumberger price target raised to $21 from $19 at JPMorgan
12/15/20 Citi
Schlumberger price target raised to $30 from $25 at Citi
12/10/20 HSBC
Schlumberger downgraded to Reduce from Hold at HSBC
11/30/20 Susquehanna
Susquehanna raises targets across Oilfield Services on cyclical rebound
KSU Kansas City Southern
$212.74 /

-2.92 (-1.35%)

01/15/21 Raymond James
Kansas City Southern price target raised to $245 from $210 at Raymond James
01/12/21 JPMorgan
Kansas City Southern price target raised to $204 from $199 at JPMorgan
01/11/21 Citi
Kansas City Southern price target raised to $250 from $220 at Citi
12/10/20 Morgan Stanley
Morgan Stanley downgrades CSX to Underweight with bar raised too high
RF Regions Financial
$17.81 /

-0.33 (-1.82%)

01/15/21 Compass Point
Regions Financial upgraded to Buy from Neutral at Compass Point
01/12/21 UBS
UBS downgrades Citizens on revenue headwinds, Wells new top pick
01/07/21 Keefe Bruyette
Regions Financial upgraded to Outperform from Market Perform at Keefe Bruyette
01/07/21 Baird
Regions Financial downgraded to Neutral from Outperform at Baird
ALLY Ally Financial
$39.93 /

-1.43 (-3.46%)

01/19/21 JPMorgan
Ally Financial price target raised to $47 from $32 at JPMorgan
01/13/21 Janney Montgomery Scott
Ally Financial price target raised to $45 from $40 at Janney Montgomery Scott
01/13/21 Credit Suisse
Ally Financial price target raised to $42 from $34 at Credit Suisse
01/13/21 Citi
Ally Financial price target raised to $45 from $33 at Citi
HBAN Huntington Bancshares
$14.51 /

-0.18 (-1.23%)

01/13/21 Piper Sandler
PNC Financial downgraded to Neutral from Overweight at Piper Sandler
01/06/21 Wedbush
Huntington Bancshares added to Best Ideas List at Wedbush
01/06/21 Deutsche Bank
Huntington Bancshares price target raised to $14 from $10.50 at Deutsche Bank
01/05/21 Piper Sandler
TCF Financial upgraded to Overweight from Neutral at Piper Sandler
FHN First Horizon
$14.34 /

-0.36 (-2.45%)

10/08/20 Jefferies
First Horizon upgraded to Buy from Hold at Jefferies
09/22/20 Raymond James
First Horizon upgraded to Strong Buy from Outperform at Raymond James
08/20/20 Goldman Sachs
First Horizon reinstated with a Buy at Goldman Sachs
08/17/20 Morgan Stanley
First Horizon resumed with an Equal Weight at Morgan Stanley
SLB Schlumberger
$24.18 /

-1.16 (-4.58%)

RF Regions Financial
$17.81 /

-0.33 (-1.82%)

KSU Kansas City Southern
$212.74 /

-2.92 (-1.35%)

HBAN Huntington Bancshares
$14.51 /

-0.18 (-1.23%)

FHN First Horizon
$14.34 /

-0.36 (-2.45%)

ALLY Ally Financial
$39.93 /

-1.43 (-3.46%)

SLB Schlumberger
$24.18 /

-1.16 (-4.58%)

RF Regions Financial
$17.81 /

-0.33 (-1.82%)

KSU Kansas City Southern
$212.74 /

-2.92 (-1.35%)

HBAN Huntington Bancshares
$14.51 /

-0.18 (-1.23%)

SLB Schlumberger
$24.18 /

-1.16 (-4.58%)

RF Regions Financial
$17.81 /

-0.33 (-1.82%)

KSU Kansas City Southern
$212.74 /

-2.92 (-1.35%)

HBAN Huntington Bancshares
$14.51 /

-0.18 (-1.23%)

FHN First Horizon
$14.34 /

-0.36 (-2.45%)

ALLY Ally Financial
$39.93 /

-1.43 (-3.46%)

SLB Schlumberger
$24.18 /

-1.16 (-4.58%)

RF Regions Financial
$17.81 /

-0.33 (-1.82%)

KSU Kansas City Southern
$212.74 /

-2.92 (-1.35%)

HBAN Huntington Bancshares
$14.51 /

-0.18 (-1.23%)

ALLY Ally Financial
$39.93 /

-1.43 (-3.46%)

Syndicate
Passage Bio 7M share Secondary priced at $22.00 » 19:53
01/21/21
01/21
19:53
01/21/21
19:53
PASG

Passage Bio

$22.84 /

-4.3 (-15.84%)

The deal priced below the…

The deal priced below the last closing price of $22.82. JPMorgan, Goldman Sachs and Cowen are acting as joint book running managers for the offering.

ShowHide Related Items >><<
PASG Passage Bio
$22.84 /

-4.3 (-15.84%)

PASG Passage Bio
$22.84 /

-4.3 (-15.84%)

01/04/21 Chardan
Lifting hold on PGBM01 a 'broad positive' for Passage Bio pipeline, says Chardan
01/04/21 JPMorgan
Passage Bio upgraded to Overweight at JPMorgan after clinical hold lifted
01/04/21 JPMorgan
Passage Bio upgraded to Overweight from Neutral at JPMorgan
12/11/20 Citi
Passage Bio initiated with a Neutral at Citi
PASG Passage Bio
$22.84 /

-4.3 (-15.84%)

  • 22
    Jan
  • 28
    Feb
PASG Passage Bio
$22.84 /

-4.3 (-15.84%)

Hot Stocks
Aclaris gets orphan drug designation in cryopyrin-associated periodic syndrome » 19:50
01/21/21
01/21
19:50
01/21/21
19:50
ACRS

Aclaris Therapeutics

$18.11 /

+0.28 (+1.57%)

Aclaris announced that…

Aclaris announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for the treatment of cryopyrin-associated periodic syndrome.Reference Link

ShowHide Related Items >><<
ACRS Aclaris Therapeutics
$18.11 /

+0.28 (+1.57%)

ACRS Aclaris Therapeutics
$18.11 /

+0.28 (+1.57%)

01/19/21 William Blair
Aclaris has potential in range of 'blockbuster indications,' says William Blair
ACRS Aclaris Therapeutics
$18.11 /

+0.28 (+1.57%)

  • 20
    Jan
ACRS Aclaris Therapeutics
$18.11 /

+0.28 (+1.57%)

Hot Stocks
Novartis Gene Therapies gets FDA Orphan Drug Designation in Friedreich's Ataxia » 19:48
01/21/21
01/21
19:48
01/21/21
19:48
NVS

Novartis

$96.83 /

-0.085 (-0.09%)

Novartis Gene Therapies…

Novartis Gene Therapies announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its "Adeno-associated virus isoform 9 gene vector construct expressing the human Frataxin gene" for the treatment of Friedreich's Ataxia. Reference Link

ShowHide Related Items >><<
NVS Novartis
$96.83 /

-0.085 (-0.09%)

NVS Novartis
$96.83 /

-0.085 (-0.09%)

01/15/21 Deutsche Bank
Novartis initiated with a Buy at Deutsche Bank
01/12/21 Piper Sandler
BeiGene price target raised to $190 from $185 at Piper Sandler
01/08/21 Morgan Stanley
Novartis price target raised to CHF 104 from CHF 102 at Morgan Stanley
01/08/21 Morgan Stanley
Roche downgraded to Equal Weight from Overweight at Morgan Stanley
NVS Novartis
$96.83 /

-0.085 (-0.09%)

NVS Novartis
$96.83 /

-0.085 (-0.09%)

NVS Novartis
$96.83 /

-0.085 (-0.09%)

Syndicate
BJ's Restaurants announces at-the-market equity program for $25M » 19:46
01/21/21
01/21
19:46
01/21/21
19:46
BJRI

BJ's Restaurants

$46.22 /

-1.17 (-2.47%)

The company currently…

The company currently intends to use the net proceeds from sales of Shares under the ATM Program for working capital and other general corporate purposes, including capital expenditures and new restaurant expansion, as well as to strengthen our balance sheet. The shares will be offered through J.P. Morgan Securities as sales agent.

ShowHide Related Items >><<
BJRI BJ's Restaurants
$46.22 /

-1.17 (-2.47%)

BJRI BJ's Restaurants
$46.22 /

-1.17 (-2.47%)

01/21/21 Deutsche Bank
BJ's Restaurants downgraded to Hold after 42% rally at Deutsche Bank
01/20/21 Deutsche Bank
BJ's Restaurants downgraded to Hold from Buy at Deutsche Bank
01/07/21 Stephens
BJ's Restaurants upgraded to Overweight on casual dining 'boom' at Stephens
01/07/21 Stephens
BJ's Restaurants upgraded to Overweight from Equal Weight at Stephens
BJRI BJ's Restaurants
$46.22 /

-1.17 (-2.47%)

BJRI BJ's Restaurants
$46.22 /

-1.17 (-2.47%)

Earnings
BJ's Restaurants sees Q4 revenue $197.0M, consensus $210.97M » 19:45
01/21/21
01/21
19:45
01/21/21
19:45
BJRI

BJ's Restaurants

$46.22 /

-1.17 (-2.47%)

Sees Q4 SSS down 32.3%. …

Sees Q4 SSS down 32.3%. Sees Q4 adj. EBITDA $2.0M-$3.0M. Sees Q4 restaurant level operating margin $12.5M-$13.5M. CEO Greg Trojan says: "BJ's fourth quarter results were impressive in light of the increasing restrictions on our dining room capacity. October results were strong with weekly sales per restaurant averaging over $83,000 and comparable restaurant sales of -20.6%, despite being limited to only outdoor seating and off-premise sales at 34 of our 62 California restaurants for at least part of the month and dining room capacity limitations at our remaining 175 restaurants. Beginning in November, rising COVID-19 cases caused numerous states to rollback dine-in re-openings, while in December, California closed all outdoor patio seating, limiting our sales in the state to only delivery and take-out. As such, sales in November and December averaged $77,600 and $60,300 per restaurant week, respectively, which equated to comparable restaurant sales of -27.0% in November and -45.3% in December. Despite these challenges, the productivity and efficiency initiatives implemented at the start of the pandemic allowed us to generate positive cash flow from operations for the quarter. Sales have been improving in the new year, which we believe reflects both high levels of pent-up guest demand and the easing of certain capacity restrictions. Comparable restaurant sales improved significantly to -37.2% for the first three weeks of January from -45.3% in December. Notably, excluding California where most restaurants remain limited to only delivery and take-out, comparable restaurant sales improved to -22.5% for the first three weeks of January. In Texas, Florida and Ohio, our three largest markets after California, comparable restaurant sales improved to -14.3% in aggregate during this same period. Colorado and Pennsylvania, where we have 10 total restaurants, re-opened their dining rooms for limited seating starting in the first week of January and outdoor seating resumed last week at five of our California restaurants. Our teams are excited to continue re-opening dining rooms when conditions permit. As we experienced in 2020 when our dining rooms re-opened for a limited time, our guests are eager to return to the differentiated, high quality and high energy BJ's dining experience."

ShowHide Related Items >><<
BJRI BJ's Restaurants
$46.22 /

-1.17 (-2.47%)

BJRI BJ's Restaurants
$46.22 /

-1.17 (-2.47%)

01/21/21 Deutsche Bank
BJ's Restaurants downgraded to Hold after 42% rally at Deutsche Bank
01/20/21 Deutsche Bank
BJ's Restaurants downgraded to Hold from Buy at Deutsche Bank
01/07/21 Stephens
BJ's Restaurants upgraded to Overweight on casual dining 'boom' at Stephens
01/07/21 Stephens
BJ's Restaurants upgraded to Overweight from Equal Weight at Stephens
BJRI BJ's Restaurants
$46.22 /

-1.17 (-2.47%)

BJRI BJ's Restaurants
$46.22 /

-1.17 (-2.47%)

Hot Stocks
Amgen granted FDA Orphan Drug Designation for carfilzomib » 19:41
01/21/21
01/21
19:41
01/21/21
19:41
AMGN

Amgen

$252.13 /

-0.28 (-0.11%)

Amgen announced that the…

Amgen announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for carfilzomib for the treatment of Acute Lymphoblastic Leukemia. Reference Link

ShowHide Related Items >><<
AMGN Amgen
$252.13 /

-0.28 (-0.11%)

AMGN Amgen
$252.13 /

-0.28 (-0.11%)

12/29/20 Daiwa
Amgen initiated with a Buy at Daiwa
12/28/20 Oppenheimer
Amgen price target lowered to $266 from $274 at Oppenheimer
12/15/20 Goldman Sachs
Amgen downgraded to Buy from Conviction Buy at Goldman Sachs
12/09/20 SVB Leerink
Amgen price target raised to $253 from $243 at SVB Leerink
AMGN Amgen
$252.13 /

-0.28 (-0.11%)

AMGN Amgen
$252.13 /

-0.28 (-0.11%)

AMGN Amgen
$252.13 /

-0.28 (-0.11%)

AMGN Amgen
$252.13 /

-0.28 (-0.11%)

Initiation
Autodesk initiated with a Sell at Goldman Sachs » 18:55
01/21/21
01/21
18:55
01/21/21
18:55
ADSK

Autodesk

$306.43 /

-2.24 (-0.73%)

Goldman Sachs analyst…

Goldman Sachs analyst Kash Rangan initiated coverage of Autodesk with a Sell rating and $270 price target. The company is a "category leader" and looks poised to grow into a dominant design, automation software company in the cloud in key end markets including architecture, engineering, construction, and manufacturing, the analyst tells investors in a research note. Rangan is concerned however that the health of Autodesk's end markets remains uncertain, adding that the company's medium-term revenue and free cash flow targets are "increasingly back end loaded".

ShowHide Related Items >><<
ADSK Autodesk
$306.43 /

-2.24 (-0.73%)

ADSK Autodesk
$306.43 /

-2.24 (-0.73%)

01/15/21 Deutsche Bank
Autodesk price target raised to $370 from $300 at Deutsche Bank
01/06/21 Barclays
Autodesk price target raised to $324 from $295 at Barclays
01/05/21 KeyBanc
Autodesk price target raised to $345 from $310 at KeyBanc
12/16/20 Mizuho
Autodesk price target raised to $340 from $290 at Mizuho
ADSK Autodesk
$306.43 /

-2.24 (-0.73%)

ADSK Autodesk
$306.43 /

-2.24 (-0.73%)

ADSK Autodesk
$306.43 /

-2.24 (-0.73%)

Initiation
Oracle initiated with a Sell at Goldman Sachs » 18:53
01/21/21
01/21
18:53
01/21/21
18:53
ORCL

Oracle

$61.19 /

-0.36 (-0.58%)

Goldman Sachs analyst…

Goldman Sachs analyst Kash Rangan initiated coverage of Oracle with a Sell rating and $60 price target. The analyst said his view of the stock is supported by the firm's DX survey; when he asked CIOs which vendors will gain or lose share in DX budgets, amongst all vendors, Oracle did not perform well.

ShowHide Related Items >><<
ORCL Oracle
$61.19 /

-0.36 (-0.58%)

ORCL Oracle
$61.19 /

-0.36 (-0.58%)

12/18/20
Fly Intel: Top five analyst upgrades
12/18/20 Monness Crespi
Monness Crespi upgrades 'value play' Oracle to Buy with $82 price target
12/18/20 Monness Crespi
Oracle upgraded to Buy from Neutral at Monness Crespi
12/17/20 Rosenblatt
LivePerson initiated with a Buy at Rosenblatt
ORCL Oracle
$61.19 /

-0.36 (-0.58%)

ORCL Oracle
$61.19 /

-0.36 (-0.58%)

ORCL Oracle
$61.19 /

-0.36 (-0.58%)

ORCL Oracle
$61.19 /

-0.36 (-0.58%)

Initiation
VMware initiated with a Neutral at Goldman Sachs » 18:52
01/21/21
01/21
18:52
01/21/21
18:52
VMW

VMware

$134.09 /

+1.46 (+1.10%)

Goldman Sachs analyst…

Goldman Sachs analyst Kash Rangan initiated coverage of VMware with a Neutral rating and $150 price target. The analyst is confident the company can hit a $20B revenue target, though there are "several" near-term headwinds. Rangan added that VMware is the "most successful" infrastructure software company to have attained scale and profitability.

ShowHide Related Items >><<
VMW VMware
$134.09 /

+1.46 (+1.10%)

VMW VMware
$134.09 /

+1.46 (+1.10%)

01/21/21
Fly Intel: Top five analyst downgrades
01/21/21 KeyBanc
KeyBanc cuts VMware to Sector Weight ahead of 'more challenging first half'
01/21/21 KeyBanc
VMware downgraded to Sector Weight from Overweight at KeyBanc
01/15/21 Evercore ISI
Evercore adds Dell Technologies to tactical Outperform list, ups target to $85
VMW VMware
$134.09 /

+1.46 (+1.10%)

VMW VMware
$134.09 /

+1.46 (+1.10%)

VMW VMware
$134.09 /

+1.46 (+1.10%)

VMW VMware
$134.09 /

+1.46 (+1.10%)

Initiation
Snowflake initiated with a Neutral at Goldman Sachs » 18:51
01/21/21
01/21
18:51
01/21/21
18:51
SNOW

Snowflake

$285.91 /

+4.05 (+1.44%)

Goldman Sachs analyst…

Goldman Sachs analyst Kash Rangan initiated coverage of Snowflake with a Neutral rating and $310 price target. The company remains "well positioned" to continue to capitalize on long-term secular tailwinds including cloud migration and secure data sharing, the analyst tells investors in a research note. Rangan further contends that the increase in digitization across verticals and corresponding growth in data will continue to drive increasing need for data analytics and business intelligence tools. The stock is trading at 87-times his 2021 sales estimate however, Rangan adds, stating that Snowflake's positives are "largely reflected" in its its current valuation.

ShowHide Related Items >><<
SNOW Snowflake
$285.91 /

+4.05 (+1.44%)

SNOW Snowflake
$285.91 /

+4.05 (+1.44%)

01/19/21 Rosenblatt
Snowflake initiated with a Neutral at Rosenblatt
01/15/21 Credit Suisse
Snowflake price target raised to $310 from $265 at Credit Suisse
01/13/21 Citi
Snowflake price target raised to $325 from $300 at Citi
01/05/21 Deutsche Bank
Deutsche cuts Snowflake target with upcoming lockup adding 87% to float
SNOW Snowflake
$285.91 /

+4.05 (+1.44%)

  • 16
    Sep
SNOW Snowflake
$285.91 /

+4.05 (+1.44%)

SNOW Snowflake
$285.91 /

+4.05 (+1.44%)

SNOW Snowflake
$285.91 /

+4.05 (+1.44%)

Initiation
Elastic initiated with a Neutral at Goldman Sachs » 18:50
01/21/21
01/21
18:50
01/21/21
18:50
ESTC

Elastic

$171.40 /

+2.57 (+1.52%)

Goldman Sachs analyst…

Goldman Sachs analyst Kash Rangan initiated coverage of Elastic with a Neutral rating and $190 price target. The analyst said his price target is based on the firm's fundamental valuation framework, adding that his thesis is that Elastic's combination of technology and differentiated customer approach has the potential to disrupt the "fragmented" IT Operations market.

ShowHide Related Items >><<
ESTC Elastic
$171.40 /

+2.57 (+1.52%)

ESTC Elastic
$171.40 /

+2.57 (+1.52%)

01/19/21 Truist
Elastic initiated with a Buy at Truist
01/15/21 Stifel
Elastic upgraded to Buy after licensing changes at Stifel
01/14/21 Stifel
Elastic upgraded to Buy from Hold at Stifel
01/13/21 Citi
Elastic price target raised to $190 from $160 at Citi
ESTC Elastic
$171.40 /

+2.57 (+1.52%)

ESTC Elastic
$171.40 /

+2.57 (+1.52%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.